ACELLULAR PERTUSSIS VACCINE

The invention relates to an acellular pertussis (aP) vaccine composition comprising Bordetella pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM), and optionally pertactin (PRN), wherein FIM is present in an amount of 12-100 µg per human dose....

Full description

Saved in:
Bibliographic Details
Main Author POOLMAN, JAN THEUNIS
Format Patent
LanguageEnglish
French
Published 12.09.2014
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The invention relates to an acellular pertussis (aP) vaccine composition comprising Bordetella pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM), and optionally pertactin (PRN), wherein FIM is present in an amount of 12-100 µg per human dose.
Bibliography:Application Number: CA20142903937